Alnylam Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
GET THE FULL COMPANY
ANALYSIS BUNDLE FOR
Alnylam
See the Bigger Picture
Alnylam’s BCG Matrix preview highlights how its RNAi therapeutics portfolio balances high-growth opportunities with cash-generating assets, revealing which programs may be Stars, Question Marks, Cash Cows, or Dogs amid shifting payer dynamics and competitive RNA platforms. This snapshot points to pipeline strengths and commercialization risks, but the full BCG Matrix delivers quadrant-by-quadrant placements, revenue forecasts, and prioritized strategic moves tailored to Alnylam’s portfolio. Purchase the complete report for an editable Word analysis + Excel summary that directs capital allocation and product strategy with data-backed clarity.
Stars
Amvuttra (Vutrisiran) Expansion
As of late 2025, Amvuttra (vutrisiran) is a Star after HELIOS-B showed a 45% relative reduction in CV hospitalization or death at 24 months, driving label expansion into ATTR cardiomyopathy and uptake in cardiology channels.
The drug leads the RNAi amyloidosis class with estimated 2025 revenue of $1.3bn and year-on-year growth of ~85%, taking share from tafamidis and diflunisal-based stabilizers.
Alnylam is pouring ~$400m annually into global commercial scaling and expects peak sales of $6–8bn, but must sustain investment to fend off emerging ASO and small-molecule competitors.
ALN-KHK for Type 2 Diabetes
ALN-KHK for Type 2 diabetes has entered late-stage development targeting the $130+ billion global diabetes market (2024 IMS Health), positioning Alnylam to disrupt standard GLP-1 and insulin-based care with RNAi’s durable mechanism; Phase 3 start expected 2025 and peak sales modeled at $6–12B annually by 2035.
Next-Generation Delivery Platforms
Alnylam’s IKARIA and advanced conjugate platforms are Stars: they enable extrahepatic targeting to CNS and adipose tissue, crucial as RNAi expands into complex indications; IKARIA-backed programs showed preclinical CNS delivery improvement of >3x (2024) versus standard GalNAc.
Mivelsiran (ALN-APP) for Alzheimer's
Mivelsiran (ALN-APP) targets the high-growth CNS field as a first-in-class RNAi drug; phase 2 data to mid-2025 showed ~60% reduction in amyloid precursor protein (APP) expression in CSF, signaling strong disease-modifying potential.
By end-2025, clinical milestones position it as a star in Alnylam’s BCG matrix with leading share in RNAi-for-neurodegeneration, but it needs >$1.2B cumulative R&D to reach approval; peak sales potential exceeds $4–6B annually if approved and adopted.
- ~60% APP CSF reduction (mid-2025)
- End-2025: leading niche share in RNAi neurodegeneration
- Estimated >$1.2B R&D to approval
- Peak sales $4–6B annually if approved
Zilebesiran for Hypertension
Zilebesiran, developed with Roche, is a Star in Alnylam’s BCG matrix targeting the global hypertension market (~1.3B people; $90B+ annual drug spend), offering a biannual RNAi shot that could reshape adherence and outcomes.
It leads long-acting RNAi for chronic disease amid strong investor interest; Phase 3 scale-up demands high cash (estimated $400–600M program spend through 2026) but positions it to become a dominant market leader.
- Biannual dosing — improves adherence vs daily pills
- Hypertension market size ~1.3B people, $90B+ spend
- Partner: Roche — boosts commercial scale
- Phase 3 cost estimate $400–600M through 2026
- High investor interest in long-acting RNAi
Alnylam's 2025 surge: Amvuttra $1.3B; multiple assets poised for $6–12B peaks
Stars: Amvuttra — 2025 rev $1.3bn, +85% YoY, peak $6–8bn; ALN-KHK (T2D) Phase 3 start 2025, modeled peak $6–12bn by 2035; IKARIA platform >3x CNS delivery (2024); Mivelsiran mid-2025 ~60% APP CSF reduction, >$1.2bn R&D to approval, peak $4–6bn; Zilebesiran (with Roche) biannual dosing, hypertension market ~1.3B patients, Phase 3 spend $400–600M.
| Asset | 2025 rev/metric | Peak $ |
|---|---|---|
| Amvuttra | $1.3bn, +85% YoY | $6–8bn |
| ALN-KHK | Phase 3 start 2025 | $6–12bn |
| Mivelsiran | ~60% APP CSF ↓ | $4–6bn |
| Zilebesiran | Hypertension ~1.3B pts | — (partner Roche) |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix of Alnylam: strategic roles, investment recommendations, competitive strengths/risks, and trend-driven quadrant impacts.
Customizable Excel Spreadsheet
One-page Alnylam BCG Matrix placing each therapeutic area in a quadrant for quick strategy decisions
Cash Cows
Onpattro (Patisiran)
Onpattro (patisiran) remains Alnylam’s foundational RNAi cash cow, holding an estimated ~40% share of the hereditary ATTR polyneuropathy market in 2024 and generating roughly $420m revenue in FY2024, with gross margins north of 70%.
Growth has slowed as patients shift to Amvuttra (vutrisiran) after its 2022 launch, but Onpattro’s predictable cash flow funds R&D; Alnylam directed about $600m of operating cash to pipeline programs in 2024, supporting multiple Question Marks.
Givlaari (Givosiran)
Givlaari (givosiran) is the market leader for Acute Hepatic Porphyria, serving ~1,800 diagnosed patients in major markets with >70% share; high clinical barriers and specialist prescribing keep churn low.
Post-launch, marketing spend fell ~60% vs peak, enabling steady positive cash flow; 2024 revenue ~USD 560M and gross margin ~78% made it a classic Cash Cow.
Its cash generation underpins Alnylam’s corporate stability, covering routine R&D and helping service debt facilities (2024 net debt ~USD 1.2B).
Oxlumo (Lumasiran)
Oxlumo (lumasiran), Alnylam’s RNAi therapy for Primary Hyperoxaluria Type 1, holds a dominant share and generated about $560 million in 2024 global net product revenue, giving steady cash flow.
The PH1 market is small and stable—incidence ~1:120,000—so volume growth is low but margin per patient stays high, with list price around $450,000–$500,000 annually in 2024.
Those predictable profits fund Alnylam’s higher-risk CNS programs, covering R&D burn and enabling pipeline expansion without diluting shareholders.
Leqvio (Inclisiran) Royalty Stream
Leqvio (inclisiran) royalties from Novartis give Alnylam a high-share, low-maintenance cash cow: 2025 global Leqvio sales reached about $2.4 billion, and Alnylam’s mid-single-digit royalty rate implies roughly $120–180 million of non-dilutive revenue, steadying Alnylam’s balance sheet while the drug remains embedded in cardiovascular guidelines.
- 2025 Leqvio sales ≈ $2.4B
- Alnylam royalty ≈ mid-single-digit % → ~$120–180M
- High market share in high-cholesterol segment
- Low maintenance: commercialized by Novartis
Established RNAi IP Licensing
Alnylam’s extensive patent estate on lipid nanoparticle delivery and siRNA chemistry produced about $220m in licensing revenue in 2024, sustaining recurring cash flows from biotech partners and contract milestones.
These licensing deals sit in a mature IP market where Alnylam retains a commanding, historical share of foundational RNAi patents, reducing competitive pressure and preserving pricing power.
Low marginal costs for managing licenses and enforcement mean high operating leverage: margins on this segment exceed 80%, making it a highly efficient cash cow for Alnylam.
- $220m licensing revenue 2024
- 80%+ segment margins
- Commanding share of foundational RNAi patents
High‑margin royalties & licensing fuel $1.8B+ revenue run, supporting R&D and debt
Onpattro, Givlaari, Oxlumo and Leqvio royalties generated steady, high-margin cash: FY2024/2025 revenues ≈ Onpattro $420M, Givlaari $560M, Oxlumo $560M, Leqvio royalties ~$120–180M; licensing ~$220M; margins often >70%, funding R&D and debt service (net debt ~$1.2B in 2024).
| Asset | FY | Revenue | Margin |
|---|---|---|---|
| Onpattro | 2024 | $420M | >70% |
| Givlaari | 2024 | $560M | ~78% |
| Oxlumo | 2024 | $560M | high |
| Leqvio royalties | 2025 | $120–180M | royalty |
| Licensing | 2024 | $220M | 80%+ |
What You See Is What You Get
Alnylam BCG Matrix
The file you're previewing on this page is the final Alnylam BCG Matrix you'll receive after purchase—no watermarks or demo content, just a fully formatted, analysis-ready report designed for strategic clarity and professional use.
Dogs
Discontinued Early-Stage Hepatic Programs
Several early-stage liver-targeted programs that failed to beat existing RNAi treatments are classified as Dogs; four programs were discontinued between 2022–2024 after phase 1/2 readouts showed no meaningful efficacy advantage versus Onpattro and Givlaari benchmarks.
These programs sat in low-growth markets—estimated CAGR below 3% and addressable populations under 50,000—which raised high commercial risk and weak peak-sales forecasts (under $50m/year each).
Alnylam largely divested or stopped further funding, cutting R&D spend on these assets by roughly $120m cumulatively in 2023–2024 to avoid cash-trap scenarios and refocus on higher-growth systemic and CNS RNAi programs.
Legacy siRNA Delivery Formulations
Legacy siRNA delivery formulations, once central to Alnylam’s pipeline, are now Dogs—first-generation lipid- and polymer-based systems overtaken by subcutaneous GalNAc conjugates that achieved >90% of approved pipeline delivery by 2024.
These legacy platforms hold single-digit market share and <2024> revenue contribution under $50M annually, with maintenance and CMC (chemistry, manufacturing, controls) overheads often exceeding their strategic value.
Niche Ultra-Rare Indications with High Competition
Certain ultra-rare disease programs where competitors reached the market first and captured the limited patient pool are now Dogs for Alnylam; for example, post-2024 launch uptake left Alnylam with under 5% share in indications totaling ~2,500 patients globally. These assets show low growth forecasts—CAGR <2% through 2029—and generated <$15m combined 2025 revenue estimates. Strategic planners recommend phasing out or divesting these programs to reallocate ~$150–200m R&D/SGA over 3 years toward Star candidates.
Non-Core Diagnostic Partnerships
Non-Core Diagnostic Partnerships are BCG Dogs: ventures into diagnostics unrelated to RNA interference (RNAi) lag revenue and market traction, generating under 5% of Alnylam Pharmaceuticals’ 2024 product revenue and holding single-digit market share in a crowded $70B global diagnostics market (2024 estimate).
These units conflict with Alnylam’s 2025 strategic focus on blockbuster RNAi medicines; divestiture or spin-off is the preferred option to cut overhead, free ~USD 20–50M in annual R&D spend, and reallocate capital to lead programs.
- Underperforming: <5% revenue contribution (2024)
- Low market share: single-digit in >$70B diagnostics market (2024)
- Strategic mismatch: 2025 focus on RNAi blockbusters
- Recommended: divestiture to free USD 20–50M/year R&D
Outdated Manufacturing Facilities
Older pilot manufacturing plants for Alnylam (siRNA leader) are Dogs: suboptimal for current siRNA scale, running at estimated utilization under 40% in 2025 and yielding substantially lower IRR versus automated sites (projected IRR ~5–7% vs 18–25%).
These assets tie up capital, give lower ROI, and are logical decommission or sale candidates—recent small-biotech plant acquisitions averaged $8–25M in 2023–24, a realistic disposal range.
- Utilization <40% (2025 est.)
- IRR ~5–7% vs modern 18–25%
- Sale value range $8–25M (2023–24 comps)
- Recommend decommission/sell to small biotech
Divest Alnylam BCG Dogs—Redeploy $170–250M into High‑Growth Systemic/CNS RNAi
Several early liver-targeted and legacy siRNA programs, select ultra-rare disease assets, non-core diagnostics, and older pilot plants are BCG Dogs for Alnylam: low growth (CAGR <3%), tiny market share (<5–10%), and weak revenue (<$50M each); recommended divestiture/decommission to reallocate ~$170–250M R&D/SGA (2023–2026) toward high-growth systemic/CNS RNAi programs.
| Asset | Growth | Market share | Revenue | Action |
|---|---|---|---|---|
| Early liver programs | <3% CAGR | <5% | <$50M | Discontinue/divest |
| Legacy delivery | <2% CAGR | single-digit | <$50M | Phase-out |
| Ultra-rare | <2% CAGR | <5% | <$15M | Sell/license |
| Diagnostics | low | <5% | <5% of 2024 rev | Spin-off |
| Pilot plants | flat | n/a | low utilization | Sell/decommission |
Question Marks
ALN-KAS for Complement-Mediated Diseases
ALN-KAS, Alnylam’s RNAi for complement-mediated diseases, is a new entrant in a high-growth market (CAGR ~12% to 2028) with low current share as it’s in Phase 2 testing (2025); market incumbents like Alexion’s SKYRIZI-class monoclonals hold dominant revenue (Alexion 2024 complement sales ~$6.1B).
Significant R&D and go-to-market spend—likely $200–400M over 2–3 years—will be needed to prove superiority and scale; without rapid clinical wins and payer evidence, ALN-KAS risks remaining a Question Mark or declining.
RNAi for Ocular Disorders
Alnylam’s RNAi for ocular disorders sits as a Question Mark: ophthalmology is a $27B global market (2024) with RNAi share <5%, so high growth potential but low current share.
Ocular delivery barriers raise technical and regulatory risk; Phase 2 GA (geographic atrophy) data to watch: expected peak sales scenarios $1–3B for a successful drug.
Management must either increase R&D spend (estimate +$200–$400M over 3 years) or partner with an eye-care specialist to share costs and cut technical risk.
ALN-BCAT for Beta-Catenin Driven Cancers
ALN-BCAT targets beta-catenin driven solid tumors, a high-growth oncology segment with global Wnt/beta-catenin market projected at ~$5.4B by 2028; program is early-stage with no proven market share and high technical risk.
RNAi delivery in solid tumors raises safety and efficacy uncertainty, so the asset consumes heavy R&D spend—Alnylam’s 2024 R&D was $1.02B, illustrating funding pressure.
This is a Question Mark: Phase 2 readouts will decide if ALN-BCAT becomes a Star with blockbuster potential or a Dog if efficacy/safety fail.
Podocyte-Targeted Kidney Programs
Podocyte-targeted RNAi for chronic kidney disease (CKD) sits as a Question Mark: Alnylam is entering a high-growth frontier with CKD affecting ~700 million people globally (2025 WHO estimate) but programs remain in discovery with low current market penetration.
Alnylam is deploying significant R&D capital—company R&D spend was $1.2B in 2024—aiming to validate clinical efficacy and capture sufficient market share to justify portfolio inclusion.
- Large addressable market: ~700M CKD patients (2025)
- High uncertainty: discovery-stage, unknown clinical success
- Heavy investment: Alnylam R&D $1.2B (2024)
- Potential scale hinge: safety, delivery to podocytes, payer access
Ex-Vivo RNAi Cell Therapy Applications
Alnylam’s position in ex-vivo RNAi cell therapy is a Question Mark: the company holds a nascent, low market share (<5% partnerships as of Q3 2025) in a fast-growing segment expected to reach ~$4.2B by 2028, but adoption is speculative and needs deep partnerships with CAR-T and iPSC developers.
If clinical uptake of RNAi-modified cells rises—projected 25–40% CAGR in early-use cases—this segment could convert to a Star quickly, driving high-margin licensing and royalty revenue.
- Low current share: <5% partnerships (Q3 2025)
- Market potential: ~$4.2B by 2028
- Key barrier: requires intensive developer collaboration
- Upside: 25–40% CAGR could make it a Star
Question-mark RNAi pipeline: massive markets, early-stage risk—Phase 2 will decide
ALN-KAS, ocular RNAi, ALN-BCAT, podocyte CKD and ex-vivo RNAi are Question Marks: large addressable markets (complement ~$6.1B sales for Alexion 2024; ocular $27B 2024; Wnt/beta-catenin ~$5.4B by 2028; CKD ~700M patients 2025; ex-vivo ~$4.2B by 2028) but low share, early-stage trials, and $200–400M+ program costs; Phase 2/partnering outcomes will decide Star vs Dog.
| Asset | Market | Stage | Key number |
|---|---|---|---|
| ALN-KAS | Complement | Phase 2 (2025) | Alexion $6.1B (2024) |
| Ocular RNAi | Ophthalmology | Phase 2 GA | $27B (2024) |
| ALN-BCAT | Oncology | Early | $5.4B (2028) |
| Podocyte CKD | Nephrology | Discovery | ~700M patients (2025) |
| Ex-vivo RNAi | Cell therapy | Nascent | $4.2B (2028) |